News

Temper Bio is revolutionizing the treatment of chronic inflammatory diseases with a novel approach based on the neurokine TAFA4. The company is extending this breakthrough therapy to address neuro-inflammation, an emerging therapeutic field with high unmet medical needs.     Paris, France, September 20th, 2024 – Temper Bio, a biotechnology...

Crucible Therapeutics develops novel therapies treating neurological diseases with significant unmet medical needs, Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal dementia (FTD).   Paris, France, Manchester and Sheffield, United-Kingdom, September 21st, 2023 - Crucible Therapeutics, a biotechnology company developing novel therapies to treat amyotrophic lateral...

  www.laigobio.com   A collaboration for the creation of a company specialized in the development of a new biological approach for the treatment of cancer and neurological disorders.   Argobio and the Oncode Institute will support the company's development to Series A financing. Utrecht (Netherlands), and Paris (France), February...

A collaboration to develop a new class of small molecule for the treatment of Parkinson's disease and other indications.   Argobio will fund the development of this innovative project up to €3 million and incorporate a new specialized biotechnology company.   With €50M in capital, Argobio and its team of experienced entrepreneurs-in-residence...

Argobio is a French start-up studio aiming at creating at least five ambitious therapeutic biotech spinouts over the next five years   Argobio has 50 M€ of share capital committed by a syndicate of complementary and strategic investors with a shared goal to develop some of Europe’s most promising biotech innovations   Argobio will incubate early-stage,...